TY - JOUR T1 - Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P4376 AU - Eva Polverino AU - Catia Cilloniz AU - Albert Gabarrus AU - Santiago Ewig AU - Tobias Welte AU - Olga Rajas AU - Alberto Capelastegui AU - Jordi Almirall AU - Antoni Torres Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P4376.abstract N2 - Objectives: To compare clinical characteristics and outcomes of CAP outpatients receiving MXF with standard therapies (levofloxacin[LVF] or amoxicillin-clavulanic acid plus azithromycin[AMC/AZT]).Methods: A retrospective analysis was conducted on300patients prospectively recorded in 4 Spanish and 2 German hospitals,(174 LVF, 75 MXF and 51 AMC/AZT). Demographic, clinical characteristics and outcomes (mortality, hospitalizations)were recorded. Since demographic and clinical data did not differ between LVX and AMC/AZT patients we analysed them together.Results.View this table:No microbiological differences were observed (S. pneumoniae in 20%[MXF], 18%[LVF+AMC/AZT]). There were no fatality cases. Five hospitalizations were described (MXF, 3; LVF, 2)and 3 of them were related to pneumonia: 1 treatment failure due to resistant S. mitis(MXF) and 2 for residual cough and pleural effusion(LVF).Conclusions: MXF was prescribed in older patients with more comorbidities but less respiratory complications. MXF showed similar efficacy to standard antibiotics, and therefore, is a valuable option for outpatient treatment of CAP. ER -